Ambu A/S
CSE:AMBU B

Watchlist Manager
Ambu A/S Logo
Ambu A/S
CSE:AMBU B
Watchlist
Price: 111.5 DKK -13.16%
Market Cap: 29.7B DKK
Have any thoughts about
Ambu A/S?
Write Note

Intrinsic Value

The intrinsic value of one AMBU B stock under the Base Case scenario is 91.21 DKK. Compared to the current market price of 111.5 DKK, Ambu A/S is Overvalued by 18%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

AMBU B Intrinsic Value
91.21 DKK
Overvaluation 18%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Ambu A/S

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for AMBU B cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about AMBU B?
Bearish
Neutral
Bullish
Discover Undervalued Stocks
Health Care Industry

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Ambu A/S

Provide an overview of the primary business activities
of Ambu A/S.

What unique competitive advantages
does Ambu A/S hold over its rivals?

What risks and challenges
does Ambu A/S face in the near future?

Summarize the latest earnings call
of Ambu A/S.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Ambu A/S.

Provide P/S
for Ambu A/S.

Provide P/E
for Ambu A/S.

Provide P/OCF
for Ambu A/S.

Provide P/FCFE
for Ambu A/S.

Provide P/B
for Ambu A/S.

Provide EV/S
for Ambu A/S.

Provide EV/GP
for Ambu A/S.

Provide EV/EBITDA
for Ambu A/S.

Provide EV/EBIT
for Ambu A/S.

Provide EV/OCF
for Ambu A/S.

Provide EV/FCFF
for Ambu A/S.

Provide EV/IC
for Ambu A/S.

Show me price targets
for Ambu A/S made by professional analysts.

What are the Revenue projections
for Ambu A/S?

How accurate were the past Revenue estimates
for Ambu A/S?

What are the Net Income projections
for Ambu A/S?

How accurate were the past Net Income estimates
for Ambu A/S?

What are the EPS projections
for Ambu A/S?

How accurate were the past EPS estimates
for Ambu A/S?

What are the EBIT projections
for Ambu A/S?

How accurate were the past EBIT estimates
for Ambu A/S?

Compare the revenue forecasts
for Ambu A/S with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Ambu A/S and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Ambu A/S against its competitors.

Analyze the profit margins
(gross, operating, and net) of Ambu A/S compared to its peers.

Compare the P/E ratios
of Ambu A/S against its peers.

Discuss the investment returns and shareholder value creation
comparing Ambu A/S with its peers.

Analyze the financial leverage
of Ambu A/S compared to its main competitors.

Show all profitability ratios
for Ambu A/S.

Provide ROE
for Ambu A/S.

Provide ROA
for Ambu A/S.

Provide ROIC
for Ambu A/S.

Provide ROCE
for Ambu A/S.

Provide Gross Margin
for Ambu A/S.

Provide Operating Margin
for Ambu A/S.

Provide Net Margin
for Ambu A/S.

Provide FCF Margin
for Ambu A/S.

Show all solvency ratios
for Ambu A/S.

Provide D/E Ratio
for Ambu A/S.

Provide D/A Ratio
for Ambu A/S.

Provide Interest Coverage Ratio
for Ambu A/S.

Provide Altman Z-Score Ratio
for Ambu A/S.

Provide Quick Ratio
for Ambu A/S.

Provide Current Ratio
for Ambu A/S.

Provide Cash Ratio
for Ambu A/S.

What is the historical Revenue growth
over the last 5 years for Ambu A/S?

What is the historical Net Income growth
over the last 5 years for Ambu A/S?

What is the current Free Cash Flow
of Ambu A/S?

Discuss the annual earnings per share (EPS)
trend over the past five years for Ambu A/S.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Ambu A/S

Current Assets 2.5B
Cash & Short-Term Investments 534m
Receivables 864m
Other Current Assets 1.1B
Non-Current Assets 4.8B
PP&E 1.2B
Intangibles 3.6B
Other Non-Current Assets 57m
Current Liabilities 986m
Accounts Payable 444m
Other Current Liabilities 542m
Non-Current Liabilities 548m
Long-Term Debt 535m
Other Non-Current Liabilities 13m
Efficiency

Earnings Waterfall
Ambu A/S

Revenue
5.3B DKK
Cost of Revenue
-2.2B DKK
Gross Profit
3.1B DKK
Operating Expenses
-2.5B DKK
Operating Income
595m DKK
Other Expenses
-145m DKK
Net Income
450m DKK

Free Cash Flow Analysis
Ambu A/S

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

In Q3 2023, Ambu reported a 15% organic revenue growth, reaching DKK 1.38 billion, driven by significant gains in the Endoscopy Solutions segment, which grew by 18%. The EBIT margin before special items was 12.9%, and the company generated DKK 163 million in free cash flow. Ambu increased its financial guidance to 12-14% organic growth and 11-13% EBIT margin for the full year. Notable product approvals include the aScope 5 series in Europe and the US. Additionally, investments in commercial operations and sustainability initiatives, like introducing bioplastics, underscore Ambu's commitment to future growth and profitability.

What is Earnings Call?
Fundamental Scores

AMBU B Profitability Score
Profitability Due Diligence

Ambu A/S's profitability score is 50/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive 3-Years Revenue Growth
Positive Revenue Growth Forecast
Positive 1-Year Revenue Growth
50/100
Profitability
Score

Ambu A/S's profitability score is 50/100. The higher the profitability score, the more profitable the company is.

AMBU B Solvency Score
Solvency Due Diligence

Ambu A/S's solvency score is 89/100. The higher the solvency score, the more solvent the company is.

High Interest Coverage
High Altman Z-Score
Long-Term Solvency
Low D/E
89/100
Solvency
Score

Ambu A/S's solvency score is 89/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

AMBU B Price Targets Summary
Ambu A/S

There are no price targets for AMBU B.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for AMBU B?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for AMBU B is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Ambu A/S Logo
Ambu A/S

Country

Denmark

Industry

Health Care

Market Cap

29.7B DKK

Dividend Yield

0%

Description

Ambu A/S engages in the development, production, and marketing of diagnostic and life-supporting devices for hospitals and rescue services. The Company’s operations are structured into three business areas: Anaesthesia, Patient Monitoring & Diagnostics and Emergency Care. The Anaesthesia business area offers a range of products such as resuscitators, face masks and laryngeal masks. The Patient Monitoring & Diagnostics business area comprises single use electrodes for cardiological and neurological examinations. The target groups for these products are hospitals, clinics, ambulance services and sleep labs. The Emergency Care business area offers ventilation bags, neck collars and manikins for first-aid training. The firm markets its products worldwide. The firm operates King Systems Inc, First Water Heathcote Ltd and Invendo Medical GmbH as subsidiaries.

Contact

Ballerup
Baltorpbakken 13
+4572252000.0
www.ambu.com

IPO

1992-03-09

Employees

4 727

Officers

Chief Executive Officer
Ms. Britt Meelby Jensen
Founder
Holger Hesse
Executive VP & CFO
Mr. Henrik Skak Bender
Chief Operations Officer
Henrik Birk
Chief Technology Officer
Mr. Finn Mohring
Director of Investor Relations & Strategic Financial Planning
Mr. Nicolai Thomsen
Show More
Director of Corporate Communications
Mikkel Trier Wagner
Chief Marketing Officer
Rummana Hasan
Head of HR Systems
Mr. Thomas Lykke Henriksen
Executive VP of Global Innovation & Chief Innovation Officer
Mr. MĂĄns Barsne
Show Less

See Also

Discover More
What is the Intrinsic Value of one AMBU B stock?

The intrinsic value of one AMBU B stock under the Base Case scenario is 91.21 DKK.

Is AMBU B stock undervalued or overvalued?

Compared to the current market price of 111.5 DKK, Ambu A/S is Overvalued by 18%.

Back to Top